tetano
Editor, Senior Moderator
BMJ Open Respir Res
. 2024 Dec 25;11(1):e002137.
doi: 10.1136/bmjresp-2023-002137. Long COVID among the first three waves of COVID-19 in Japan: a multicentre cohort study
Hatsuyo Takaoka[SUP] 1 [/SUP], Ichiro Kawada[SUP] 2 3 [/SUP], Gaku Hiruma[SUP] 4 [/SUP], Kengo Nagashima[SUP] 5 [/SUP], Hideki Terai[SUP] 1 6 [/SUP], Noriyuki Ishida[SUP] 4 [/SUP], Ho Namkoong[SUP] 1 7 [/SUP], Takanori Asakura[SUP] 1 8 9 [/SUP], Katsunori Masaki[SUP] 1 [/SUP], Jun Miyata[SUP] 1 [/SUP], Shotaro Chubachi[SUP] 1 [/SUP], Keiko Ohgino[SUP] 1 [/SUP], Kengo Otsuka[SUP] 10 [/SUP], Naoki Miyao[SUP] 10 [/SUP], Toshio Odani[SUP] 11 [/SUP], Mayuko Watase[SUP] 1 12 [/SUP], Rie Baba[SUP] 13 [/SUP], Satoshi Okamori[SUP] 13 [/SUP], Daisuke Arai[SUP] 13 [/SUP], Ichiro Nakachi[SUP] 13 [/SUP], Naota Kuwahara[SUP] 14 [/SUP], Akiko Fujiwara[SUP] 14 [/SUP], Takenori Okada[SUP] 14 [/SUP], Takashi Ishiguro[SUP] 15 [/SUP], Taisuke Isono[SUP] 15 [/SUP], Makoto Ishii[SUP] 16 [/SUP], Yasunori Sato[SUP] 17 [/SUP], Koichi Fukunaga[SUP] 1 [/SUP]
Affiliations
Objectives: Severe acute respiratory syndrome coronavirus 2 significantly impacts Japan with a high number of infections and deaths reported. Long coronavirus disease (COVID) characterised by persistent symptoms after COVID-19 has gained recognition but varies across studies. This study aimed to investigate the differences in long COVID among patients hospitalised during Japan's first three waves of the pandemic.
Design: Multicentre prospective cohort study.
Setting: 26 medical facilities across Japan between February 2020 and February 2021.
Participants: In total, 1066 hospitalised patients diagnosed with COVID-19 were included with 206, 301 and 559 patients in the first, second and third waves, respectively. Data were collected using electronic data capture and patient-reported outcome forms.
Primary and secondary outcome measures: Long COVID was assessed at 3, 6 and 12 months after COVID-19 diagnosis.
Results: Significant differences were observed between the waves in various baseline and clinical characteristics such as age, body mass index (BMI), comorbidities, the severity of COVID-19, complications and treatment during hospitalisation. Long COVID, particularly dyspnoea, was most prevalent in the first wave. Multivariate logistic regression analysis confirmed a significant positive association between the first wave and long COVID including dyspnoea after adjusting for age, sex, BMI, smoking status and COVID-19 severity.
Conclusions: Patients hospitalised during the first wave had a higher risk of experiencing long COVID, especially dyspnoea, than those hospitalised during the other waves. These findings underscore the need for continued monitoring and managing long COVID in COVID-19 survivors, particularly in those hospitalised during the first wave.
Trial registration number: UMIN000042299.
Keywords: COVID-19; Infection Control.
. 2024 Dec 25;11(1):e002137.
doi: 10.1136/bmjresp-2023-002137. Long COVID among the first three waves of COVID-19 in Japan: a multicentre cohort study
Hatsuyo Takaoka[SUP] 1 [/SUP], Ichiro Kawada[SUP] 2 3 [/SUP], Gaku Hiruma[SUP] 4 [/SUP], Kengo Nagashima[SUP] 5 [/SUP], Hideki Terai[SUP] 1 6 [/SUP], Noriyuki Ishida[SUP] 4 [/SUP], Ho Namkoong[SUP] 1 7 [/SUP], Takanori Asakura[SUP] 1 8 9 [/SUP], Katsunori Masaki[SUP] 1 [/SUP], Jun Miyata[SUP] 1 [/SUP], Shotaro Chubachi[SUP] 1 [/SUP], Keiko Ohgino[SUP] 1 [/SUP], Kengo Otsuka[SUP] 10 [/SUP], Naoki Miyao[SUP] 10 [/SUP], Toshio Odani[SUP] 11 [/SUP], Mayuko Watase[SUP] 1 12 [/SUP], Rie Baba[SUP] 13 [/SUP], Satoshi Okamori[SUP] 13 [/SUP], Daisuke Arai[SUP] 13 [/SUP], Ichiro Nakachi[SUP] 13 [/SUP], Naota Kuwahara[SUP] 14 [/SUP], Akiko Fujiwara[SUP] 14 [/SUP], Takenori Okada[SUP] 14 [/SUP], Takashi Ishiguro[SUP] 15 [/SUP], Taisuke Isono[SUP] 15 [/SUP], Makoto Ishii[SUP] 16 [/SUP], Yasunori Sato[SUP] 17 [/SUP], Koichi Fukunaga[SUP] 1 [/SUP]
Affiliations
- PMID: 39721744
- DOI: 10.1136/bmjresp-2023-002137
Objectives: Severe acute respiratory syndrome coronavirus 2 significantly impacts Japan with a high number of infections and deaths reported. Long coronavirus disease (COVID) characterised by persistent symptoms after COVID-19 has gained recognition but varies across studies. This study aimed to investigate the differences in long COVID among patients hospitalised during Japan's first three waves of the pandemic.
Design: Multicentre prospective cohort study.
Setting: 26 medical facilities across Japan between February 2020 and February 2021.
Participants: In total, 1066 hospitalised patients diagnosed with COVID-19 were included with 206, 301 and 559 patients in the first, second and third waves, respectively. Data were collected using electronic data capture and patient-reported outcome forms.
Primary and secondary outcome measures: Long COVID was assessed at 3, 6 and 12 months after COVID-19 diagnosis.
Results: Significant differences were observed between the waves in various baseline and clinical characteristics such as age, body mass index (BMI), comorbidities, the severity of COVID-19, complications and treatment during hospitalisation. Long COVID, particularly dyspnoea, was most prevalent in the first wave. Multivariate logistic regression analysis confirmed a significant positive association between the first wave and long COVID including dyspnoea after adjusting for age, sex, BMI, smoking status and COVID-19 severity.
Conclusions: Patients hospitalised during the first wave had a higher risk of experiencing long COVID, especially dyspnoea, than those hospitalised during the other waves. These findings underscore the need for continued monitoring and managing long COVID in COVID-19 survivors, particularly in those hospitalised during the first wave.
Trial registration number: UMIN000042299.
Keywords: COVID-19; Infection Control.